Losartan for Patients With COVID-19 Not Requiring Hospitalization

Acute Respiratory Distress Syndrome Clinical Trial

Official title:

Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04311177
• Other study ID #: SURG-2020-28683
• Status: Completed
• Phase: Phase 2
• Start date: April 9, 2020
• Est. completion date: February 1, 2021

Study information

• Verified date: May 2022
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 117
• Est. completion date: February 1, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Positive laboratory test for COVID-19 based on local laboratory standard
• Age greater than or equal to 18 years of age
• One of the following: Upper respiratory symptoms (cough, rhinorrhea) or fever (>101.5) or loss of taste / smell

Exclusion Criteria:

• Randomization > 72 hours of meeting inclusion criteria
• Randomization > 7 days of symptom onset
• Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
• Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to angioedema
• Pregnant or breastfeeding women
• Females able to have children not currently taking a protocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate/Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized commitment to taking daily throughout the study, condom use or abstinence during the study. All participants of child bearing potential enrolled in this fashion will be informed of the teratogenic risks.
• Patient reported history or electronic medical record history of kidney disease,

defined as:

1. Any history of dialysis

2. History of chronic kidney disease stage IV

3. Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 (must be have been measured within 1 month of enrollment)

4. Other kidney disease that in the opinion of the investigator, would affect losartan clearance

• Patient reported dehydration and significantly decreased urine output in the past 72 hours
• Most recent systolic blood pressure prior to enrollment <110 mmHg
• Patient reported history or electronic medical record history of severe liver disease,

defined as:

1. Cirrhosis

2. History of hepatitis B or C

3. Other liver disease that in the opinion of the investigator, would affect losartan clearance

4. Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record)

• Potassium >5.0 mmol/L (must have been measured within 1 month) of enrollment
• Concurrent treatment with aliskiren
• Inability to obtain informed consent
• Enrollment in another blinded randomized clinical trial for COVID

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Communicable Diseases
• Corona Virus Infection
• Coronavirus Infections
• COVID-19
• Infections
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• SARS-CoV Infection

Intervention

Drug:
• Losartan
Losartan; 25 mg daily; oral administration

Other:
• Placebo
Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Locations

Country	Name	City	State
United States	Hennepin County Medical Center	Minneapolis	Minnesota
United States	M Health Fairview University of Minnesota Medical Center	Minneapolis	Minnesota
United States	University of Minnesota	Minneapolis	Minnesota
United States	Mayo Clinic Health System	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

References & Publications (1)

Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, Biros MH, Bellolio F, Chipman JG, Nelson AC, Beckman K, Langlois R, Bold T, Aliota MT, Schacker TW, Voelker HT, Murray TA, Koopmeiners JS, Tignanelli CJ. A multi-center phase II ran — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Admitted to the Hospital	Outcome reported as the percentage of participants per arm admitted to inpatient hospital care due to COVID-19-related disease within 15 days of randomization.; Currently, there is a pre-planned pooled analysis with a national trial network under development.	15 days
Secondary	Change in PROMIS Dyspnea Scale	The PROMIS dyspnea scale consists of 4 subscales. 3 (1. general shortness of breath, 2. intensity, and 3. Frequency) are scored from 0 (no symptoms) to 10 (most severe). The 4th subscale is scored from 0-4 in response to the question "I've been short of breath" with 0 representing none and 4 the most severe, for a total range of 0-34. Results are difference between enrollment and day 10. There are no units.	10 days
Secondary	Change in SF-12 Physical Composite Score	The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Physical score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity.	10 days
Secondary	Change in SF-12 Mental Composite Score	The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Mental composite score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.	10 days
Secondary	Daily Maximum Temperature	Participants will report their maximum daily oral temperature to the study team. Outcome is reported as the mean maximum daily body temperature (in degrees Celsius) over 10 days.	10 days
Secondary	Count of Participants With an Emergency Department or Clinic Presentation	Outcome is reported as the mean number of emergency department and clinic presentations combined per participant in each arm.	28 days
Secondary	Disease Severity Rating Day 15	Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.	15 days
Secondary	Change in Viral Load by Nasopharyngeal Swab at Day 9	Viral load is measured as number of viral genetic copies per mL.	9 days
Secondary	Change in Viral Load by Nasopharyngeal Swab at Day 15	Viral load is measured as number of viral genetic copies per mL.	15 days
Secondary	Percentage of Patients Admitted to the Intensive Care Unit Within 15 Days	Outcome reported as the percent of participants in each arm who require ICU admission by day 15 following randomization.	15 days
Secondary	Need for Oxygen Therapy at 15 Days	Outcome reported as the percent of participants in each arm who require oxygen therapy by day 15 following randomization.	15 days